A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

Go Back to All Clinical Trials

A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

Brief description of study

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

Clinical Study Identifier: s23-01214

ClinicalTrials.gov Identifier: NCT06109779

Principal Investigator: Jennifer Wu.

Other Investigators: Theresa Ryan, Daniel J Becker, Cristian C Papazoglu Statescu, Andrea Popescu-Martinez, Paul E. Oberstein, Kristen Spencer, Jason E Sandler, Keriann M Scavone, Nina Beri, Jennifer Chuy, Kenneth Csehak, Rafael Winograd, Shun Yu, Mary Lynn R Nierodzik.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies